Keryx Biopharma (KERX) Misses Q2 EPS by 59c

Keryx Biopharma (NASDAQ: KERX) reported Q2 EPS of ($0.77), $0.59 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $15.1 million versus the consensus estimate of $14.51 million.

Full year 2017 net U.S Auryxia product sales guidance increased to $62 to $66 million

For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c